留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

间充质干细胞疗法在肾移植中的应用:一个未完待续的故事

谢思雨, 路君. 间充质干细胞疗法在肾移植中的应用:一个未完待续的故事[J]. 器官移植, 2024, 15(3): 398-405. doi: 10.3969/j.issn.1674-7445.2023228
引用本文: 谢思雨, 路君. 间充质干细胞疗法在肾移植中的应用:一个未完待续的故事[J]. 器官移植, 2024, 15(3): 398-405. doi: 10.3969/j.issn.1674-7445.2023228
Xie Siyu, Lu Jun. Application of mesenchymal stem cell therapy in kidney transplantation: a continued story[J]. ORGAN TRANSPLANTATION, 2024, 15(3): 398-405. doi: 10.3969/j.issn.1674-7445.2023228
Citation: Xie Siyu, Lu Jun. Application of mesenchymal stem cell therapy in kidney transplantation: a continued story[J]. ORGAN TRANSPLANTATION, 2024, 15(3): 398-405. doi: 10.3969/j.issn.1674-7445.2023228

间充质干细胞疗法在肾移植中的应用:一个未完待续的故事

doi: 10.3969/j.issn.1674-7445.2023228
基金项目: 福建省自然科学基金面上项目(2023J01207);中国人民解放军联勤保障部队第九〇〇医院重点学科支撑项目(2023XKYZ01)
详细信息
    作者简介:
    通讯作者:

    路君(ORCID 0000-0003-2221-1872),Email:junlu.heather@xmu.edu.cn

  • 中图分类号: R617,R329.2

Application of mesenchymal stem cell therapy in kidney transplantation: a continued story

More Information
  • 摘要: 免疫抑制药是预防器官移植术后排斥反应的主要手段,但会降低机体对病原体的反应能力,导致感染等的风险增加。近年来,间充质干细胞(MSC)疗法在实体器官移植领域的应用备受关注。临床前研究表明,MSC疗法能够延长移植肾存活时间,诱导免疫耐受,加速急性肾损伤修复,促进肾功能恢复。临床试验则验证了MSC疗法的安全性、耐受性和有效性。因此,本文对MSC的一般特性、MSC的免疫调节和组织修复作用以及MSC在肾移植临床试验中的应用进行综述,简要讨论待继续研究的问题和对未来的展望,旨在为推动MSC治疗在临床肾移植中的应用提供参考。

     

  • [1] GUO Z, LUO T, MO R, et al. Ischemia-free organ transplantation - a review[J]. Curr Opin Organ Transplant, 2022, 27(4): 300-304. DOI: 10.1097/MOT.0000000000000998.
    [2] MASSICOTTE-AZARNIOUCH D, DETWILER RK, HU Y, et al. Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis[J]. Nephrol Dial Transplant, 2023, 38(9): 2009-2018. DOI: 10.1093/ndt/gfac337.
    [3] YOHANNAN B, SRIDHAR A, KAUR H, et al. Screening for renal cell carcinoma in renal transplant recipients: a single-centre retrospective study[J]. BMJ Open, 2023, 13(9): e071658. DOI: 10.1136/bmjopen-2023-071658.
    [4] 邱煜程, 周显玉, 刘菲, 等. 间充质干细胞及其外泌体在移植中的应用进展[J]. 组织工程与重建外科杂志, 2023, 19(2): 184-188. DOI: 10.3969/j.issn.1673-0364.2023.02.016.

    QIU YC, ZHOU XY, LIU F, et al. Application progress of mesenchymal stem cells and their exosomes in allotransplantation[J]. J Tissue Eng Reconstr Surg, 2023, 19(2): 184-188. DOI: 10.3969/j.issn.1673-0364.2023.02.016.
    [5] 冯星, 靳洪涛, 马隽, 等. 间充质干细胞治疗炎性关节炎的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(2): 87-92. DOI: 10.3877/cma.j.issn.2095-1221.2023.02.004.

    FENG X, JI HT, MA J, et al. Progress in the treatment of inflammatory arthritis with mesenchymal stem cells[J/OL]. Chin J Cell Stem Cell (Electr Edit), 2023, 13(2): 87-92. DOI: 10.3877/cma.j.issn.2095-1221.2023.02.004.
    [6] MARGIANA R, MARKOV A, ZEKIY AO, et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review[J]. Stem Cell Res Ther, 2022, 13(1): 366. DOI: 10.1186/s13287-022-03054-0.
    [7] ZANG L, LI Y, HAO H, et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial[J]. Stem Cell Res Ther, 2022, 13(1): 180. DOI: 10.1186/s13287-022-02848-6.
    [8] SINGH J, SINGH S. Review on kidney diseases: types, treatment and potential of stem cell therapy[J]. Ren Replace Ther, 2023, 9(1): 21. DOI: 10.1186/s41100-023-00475-2.
    [9] 高世春, 冯一梅, 高蕾, 等. 维多珠单抗治疗糖皮质激素耐药急性肠道移植物抗宿主病2例报告并文献复习[J]. 中华血液学杂志, 2022, 43(12): 1046-1049. DOI: 10.3760/cma.j.issn.0253-2727.2022.12.013.

    GAO SC, FENG YM, GAO L, et al. Vedolizumab for treatment of steroid-refractory intestinal acute graft-versus-host disease: two cases report and literature review[J]. Chin J Hematol, 2022, 43(12): 1046-1049. DOI: 10.3760/cma.j.issn.0253-2727.2022.12.013.
    [10] DOMINICI M, LE BLANC K, MUELLER I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. the International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8(4): 315-317. DOI: 10.1080/14653240600855905.
    [11] HUANG Y, WU Q, TAM PKH. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications[J]. Int J Mol Sci, 2022, 23(17): 10023. DOI: 10.3390/ijms231710023.
    [12] SEL FA, OGUZ FS. Regenerative medicine application of mesenchymal stem cells[J]. Adv Exp Med Biol, 2022, 1387: 25-42. DOI: 10.1007/5584_2022_713.
    [13] ZARIPOVA LN, MIDGLEY A, CHRISTMAS SE, et al. Mesenchymal stem cells in the pathogenesis and therapy of autoimmune and autoinflammatory diseases[J]. Int J Mol Sci, 2023, 24(22): 16040. DOI: 10.3390/ijms242216040.
    [14] PISTOIA V, RAFFAGHELLO L. Mesenchymal stromal cells and autoimmunity[J]. Int Immunol, 2017, 29(2): 49-58. DOI: 10.1093/intimm/dxx008.
    [15] DEO D, MARCHIONI M, RAO P. Mesenchymal stem/stromal cells in organ transplantation[J]. Pharmaceutics, 2022, 14(4): 791. DOI: 10.3390/pharmaceutics14040791.
    [16] DE MARTINO M, ZONTA S, RAMPINO T, et al. Mesenchymal stem cells infusion prevents acute cellular rejection in rat kidney transplantation[J]. Transplant Proc, 2010, 42(4): 1331-1335. DOI: 10.1016/j.transproceed. 2010.03.079.
    [17] 洪政, 王峰. 间充质干细胞在同种异体心脏移植中诱导免疫耐受的进展[J]. 湖北民族大学学报(医学版), 2022, 39(4): 56-59.

    HONG Z, WANG F. Progress of mesenchymal stem cells inducing immune tolerance in allogeneic heart transplantation[J]. J Hubei Univ (Med Edit), 2022, 39(4): 56-59.
    [18] GARCIA SG, SANDOVAL-HELLÍN N, CLOS-SANSALVADOR M, et al. Mesenchymal stromal cells induced regulatory B cells are enriched in extracellular matrix genes and IL-10 independent modulators[J]. Front Immunol, 2022, 13: 957797. DOI: 10.3389/fimmu.2022.957797.
    [19] FOUZA A, TAGKOUTA A, DAOUDAKI M, et al. Exploring perturbations in peripheral B cell memory subpopulations early after kidney transplantation using unsupervised machine learning[J]. J Clin Med, 2023, 12(19): 6331. DOI: 10.3390/jcm12196331.
    [20] UNAR A, BERTOLINO L, PATAUNER F, et al. Decoding sepsis-induced disseminated intravascular coagulation: a comprehensive review of existing and emerging therapies[J]. J Clin Med, 2023, 12(19): 6128. DOI: 10.3390/jcm12196128.
    [21] YANG S, ZHAO M, JIA S. Macrophage: key player in the pathogenesis of autoimmune diseases[J]. Front Immunol, 2023, 14: 1080310. DOI: 10.3389/fimmu.2023.1080310.
    [22] GAO S, MAO F, ZHANG B, et al. Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-κB and signal transducer and activator of transcription 3 pathways[J]. Exp Biol Med (Maywood), 2014, 239(3): 366-375. DOI: 10.1177/1535370213518169.
    [23] SCHRODT MV, BEHAN-BUSH RM, LISZEWSKI JN, et al. Efferocytosis of viable versus heat-inactivated MSC induces human monocytes to distinct immunosuppressive phenotypes[J]. Stem Cell Res Ther, 2023, 14(1): 206. DOI: 10.1186/s13287-023-03443-z.
    [24] 蔡海军. 间充质干细胞在组织修复和再生中应用的研究进展[J]. 重庆医学, 2023, 52(5): 782-786. DOI: 10.3969/j.issn.1671-8348.2023.05.030.

    CAI HJ. Advances in the application of mesenchymal stem cells in tissue repair and regeneration[J]. Chongqing Med, 2023, 52(5): 782-786. DOI: 10.3969/j.issn.1671-8348.2023.05.030.
    [25] YANG J, XIAO M, MA K, et al. Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: atopic dermatitis and psoriasis[J]. Front Immunol, 2023, 14: 1092668. DOI: 10.3389/fimmu.2023.1092668.
    [26] BLONDEEL J, GILBO N, DE BONDT S, et al. Stem cell derived extracellular vesicles to alleviate ischemia-reperfusion injury of transplantable organs. a systematic review[J]. Stem Cell Rev Rep, 2023, 19(7): 2225-2250. DOI: 10.1007/s12015-023-10573-7.
    [27] PODESTÀ MA, REMUZZI G, CASIRAGHI F. Mesenchymal stromal cell therapy in solid organ transplantation[J]. Front Immunol, 2021, 11: 618243. DOI: 10.3389/fimmu.2020.618243.
    [28] FRANQUESA M, HERRERO E, TORRAS J, et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model[J]. Stem Cells Dev, 2012, 21(17): 3125-3135. DOI: 10.1089/scd.2012.0096.
    [29] 马元, 庄雪莹, 陈旭. 间充质干细胞外泌体调控血管生成机制的研究进展[J]. 中国医科大学学报, 2021, 50(10): 944-947. DOI: 10.12007/j.issn.0258-4646.2021.10.016.

    MA Y, ZHUANG XY, CHEN X. Advances in research regarding the mechanisms whereby mesenchymal stem cell-derived exosomes regulate angiogenesis[J]. J China Med Univ, 2021, 50(10): 944-947. DOI: 10.12007/j.issn.0258-4646.2021.10.016.
    [30] LEE K, JANG HR. Role of T cells in ischemic acute kidney injury and repair[J]. Korean J Intern Med, 2022, 37(3): 534-550. DOI: 10.3904/kjim.2021.526.
    [31] RAMA I, GRINYÓ JM. Malignancy after renal transplantation: the role of immunosuppression[J]. Nat Rev Nephrol, 2010, 6(9): 511-519. DOI: 10.1038/nrneph.2010.102.
    [32] PERICO N, CASIRAGHI F, TODESCHINI M, et al. Long-term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy[J]. Front Immunol, 2018, 9: 1359. DOI: 10.3389/fimmu.2018.01359.
    [33] TAN J, WU W, XU X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial[J]. JAMA, 2012, 307(11): 1169-1177. DOI: 10.1001/jama.2012.316.
    [34] MUDRABETTU C, KUMAR V, RAKHA A, et al. Safety and efficacy of autologous mesenchymal stromal cells transplantation in patients undergoing living donor kidney transplantation: a pilot study[J]. Nephrology (Carlton), 2015, 20(1): 25-33. DOI: 10.1111/nep.12338.
    [35] REINDERS ME, DE FIJTER JW, ROELOFS H, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study[J]. Stem Cells Transl Med, 2013, 2(2): 107-111. DOI: 10.5966/sctm.2012-0114.
    [36] PENG Y, KE M, XU L, et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study[J]. Transplantation, 2013, 95(1): 161-168. DOI: 10.1097/TP.0b013e3182754c53.
    [37] PAN GH, CHEN Z, XU L, et al. Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study[J]. Oncotarget, 2016, 7(11): 12089-12101. DOI: 10.18632/oncotarget.7725.
    [38] LEE H, PARK JB, LEE S, et al. Intra-osseous injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney transplantation; a pilot study[J]. J Transl Med, 2013, 11: 96. DOI: 10.1186/1479-5876-11-96.
    [39] SUN Q, HUANG Z, HAN F, et al. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial[J]. J Transl Med, 2018, 16(1): 52. DOI: 10.1186/s12967-018-1422-x.
    [40] ERPICUM P, WEEKERS L, DETRY O, et al. Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study[J]. Kidney Int, 2019, 95(3): 693-707. DOI: 10.1016/j.kint.2018.08.046.
    [41] DREYER GJ, GROENEWEG KE, HEIDT S, et al. Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: the Neptune study, a phase I single-center study[J]. Am J Transplant, 2020, 20(10): 2905-2915. DOI: 10.1111/ajt.15910.
    [42] WU X, WANG Z, WANG J, et al. Exosomes secreted by mesenchymal stem cells induce immune tolerance to mouse kidney transplantation via transporting lncRNA DANCR[J]. Inflammation, 2022, 45(1): 460-475. DOI: 10.1007/s10753-021-01561-5.
    [43] 曾可君, 杨煜辉, 胡喆. 外泌体在重要脏器缺血再灌注损伤中的治疗作用研究进展[J]. 中国医药导报, 2022, 19(25): 33-37. DOI: 10.20047/j.issn1673-7210.2022.25.07.

    ZENG KJ, YANG YH, HU Z. Research progress on the therapeutical effect of exosomes in ischemia reperfusion injury in important organs[J]. China Med Herald, 2022, 19(25): 33-37. DOI: 10.20047/j.issn1673-7210.2022.25.07.
    [44] CAO Q, HUANG C, CHEN XM, et al. Mesenchymal stem cell-derived exosomes: toward cell-free therapeutic strategies in chronic kidney disease[J]. Front Med (Lausanne), 2022, 9: 816656. DOI: 10.3389/fmed.2022.816656.
    [45] KERN S, EICHLER H, STOEVE J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue[J]. Stem Cells, 2006, 24(5): 1294-1301. DOI: 10.1634/stemcells.2005-0342.
    [46] ABBASI B, SHAMSASENJAN K, AHMADI M, et al. Mesenchymal stem cells and natural killer cells interaction mechanisms and potential clinical applications[J]. Stem Cell Res Ther, 2022, 13(1): 97. DOI: 10.1186/s13287-022-02777-4.
    [47] CROP MJ, BAAN CC, KOREVAAR SS, et al. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients[J]. Transplantation, 2009, 87(6): 896-906. DOI: 10.1097/TP.0b013e31819b3d72.
    [48] NAUTA AJ, WESTERHUIS G, KRUISSELBRINK AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting[J]. Blood, 2006, 108(6): 2114-2120. DOI: 10.1182/blood-2005-11-011650.
    [49] BURON F, PERRIN H, MALCUS C, et al. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells[J]. Transplant Proc, 2009, 41(8): 3347-3352. DOI: 10.1016/j.transproceed.2009.08.030.
    [50] POPP FC, EGGENHOFER E, RENNER P, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate[J]. Transpl Immunol, 2008, 20(1/2): 55-60. DOI: 10.1016/j.trim.2008.08.004.
    [51] GE W, JIANG J, BAROJA ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance[J]. Am J Transplant, 2009, 9(8): 1760-1772. DOI: 10.1111/j.1600-6143.2009.02721.x.
    [52] KAUNDAL U, BAGAI U, RAKHA A. Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation[J]. J Transl Med, 2018, 16(1): 31. DOI: 10.1186/s12967-018-1403-0.
    [53] PERICO N, CASIRAGHI F, INTRONA M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility[J]. Clin J Am Soc Nephrol, 2011, 6(2): 412-422. DOI: 10.2215/CJN.04950610.
    [54] CASIRAGHI F, AZZOLLINI N, TODESCHINI M, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation[J]. Am J Transplant, 2012, 12(9): 2373-2383. DOI: 10.1111/j.1600-6143.2012.04115.x.
    [55] WU B, SHI X, JIANG M, et al. Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment[J]. Mol Cancer, 2023, 22(1): 38. DOI: 10.1186/s12943-023-01748-4.
    [56] GNIADEK TJ, GARRITSEN HSP, STRONCEK D, et al. Optimal storage conditions for apheresis research (OSCAR): a biomedical excellence for safer transfusion (BEST) Collaborative study[J]. Transfusion, 2018, 58(2): 461-469. DOI: 10.1111/trf.14429.
    [57] DRELA K, STANASZEK L, NOWAKOWSKI A, et al. Experimental strategies of mesenchymal stem cell propagation: adverse events and potential risk of functional changes[J]. Stem Cells Int, 2019: 7012692. DOI: 10.1155/2019/7012692.
    [58] LECHANTEUR C, BRIQUET A, BETTONVILLE V, et al. MSC manufacturing for academic clinical trials: from a clinical-grade to a full GMP-compliant process[J]. Cells, 2021, 10(6): 1320. DOI: 10.3390/cells10061320.
  • 加载中
图(1)
计量
  • 文章访问数:  78
  • HTML全文浏览量:  29
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-11-02
  • 网络出版日期:  2024-02-29
  • 刊出日期:  2024-05-07

目录

    /

    返回文章
    返回